129 related articles for article (PubMed ID: 8746073)
21. [Sequential calcitriol-calcitonin in the therapy of osteoporosis].
Passeri M; Palummeri E; Barbagallo M; Butturini L; Pedrazzoni M; Davoli L; Pioli G; Benassi L; Girasole G; Ciotti G
Minerva Endocrinol; 1989; 14(1):57-62. PubMed ID: 2659953
[TBL] [Abstract][Full Text] [Related]
22. Effect of calcitonin or the anabolic steroid Decadurabolin on serum beta 2 microglobulin in osteoporotic postmenopausal women.
Cantatore FP; Loperfido MC; Mancini L; Carrozzo M
J Rheumatol; 1992 Nov; 19(11):1753-5. PubMed ID: 1491396
[TBL] [Abstract][Full Text] [Related]
23. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
24. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
[TBL] [Abstract][Full Text] [Related]
25. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
[TBL] [Abstract][Full Text] [Related]
26. [The effects of progestin on the bone metabolism in postmenopausal women].
Ren Y; Zhu G
Zhonghua Fu Chan Ke Za Zhi; 1995 Mar; 30(3):135-7. PubMed ID: 7796643
[TBL] [Abstract][Full Text] [Related]
27. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.
Overgaard K; Hansen MA; Dirksen KL; Christiansen C
Calcif Tissue Int; 1992 Sep; 51(3):184-8. PubMed ID: 1422962
[TBL] [Abstract][Full Text] [Related]
28. [Modification of cortical and trabecular mineral density of the femur, induced by ipriflavone therapy, Clinical results after 12 months].
Fiore CE; Gibilaro M; Motta M; Foti R; Dieli M
Clin Ter; 1995 Jan; 146(1):13-9. PubMed ID: 7705009
[TBL] [Abstract][Full Text] [Related]
29. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
30. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
31. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
Melis GB; Cagnacci A; Bruni V; Falsetti L; Jasonni VM; Nappi C; Polatti F; Volpe A
Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
[TBL] [Abstract][Full Text] [Related]
32. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
33. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
[TBL] [Abstract][Full Text] [Related]
34. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
[TBL] [Abstract][Full Text] [Related]
35. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
Agnusdei D; Adami S; Cervetti R; Crepaldi G; Di Munno O; Fantasia L; Isaia GC; Letizia G; Ortolani S; Passeri M
Bone Miner; 1992 Oct; 19 Suppl 1():S43-8. PubMed ID: 1422320
[TBL] [Abstract][Full Text] [Related]
36. The importance of urinary hydroxyproline and serumal osteocalcin in the evaluation of post-menopausal osteoporosis.
Gnudi S; Ripamonti C; Bonini AM; Pratelli L; Figus E
Ital J Orthop Traumatol; 1990 Dec; 16(4):551-7. PubMed ID: 2099937
[TBL] [Abstract][Full Text] [Related]
37. Calcitonin reserve and the differentiated response to calcitonin in osteoporosis.
Vlăduţiu T; Lopez A; Gozariu L; Barabaş E
Endocrinologie; 1990; 28(3-4):139-47. PubMed ID: 2103972
[TBL] [Abstract][Full Text] [Related]
38. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
Kraenzlin ME; Seibel MJ; Trechsel U; Boerlin V; Azria M; Kraenzlin CA; Haas HG
Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
[TBL] [Abstract][Full Text] [Related]
39. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
Ohta H; Komukai S; Makita K; Masuzawa T; Nozawa S
Horm Res; 1999; 51(4):178-83. PubMed ID: 10474019
[TBL] [Abstract][Full Text] [Related]
40. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
